CRLF2 and acute lymphoblastic leukemia: Qin et al. (25) constructed an effective anti-TSLPR CAR T-cell design to eliminate TSLPR-overexpressing ALL cells in animal models, with comparable antileukemia efficacy of CD19 CARs.